PDCD1 and melanoma: More recently, de Coana et al. [40] have shown that high expression of PD‐L1 on monocyte subpopulations correlates with shorter survival in patients with melanoma who received PD‐1 blockade therapy, suggesting that expression of PD‐L1 on monocytes may affect tumour response to cytotoxic therapies.